{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-22-019857","form_type":"8-K","ticker":"ACHV","cik":"0000949858","company_name":"ACHIEVE LIFE SCIENCES, INC.","filed_at":"2022-05-12T23:59:59+00:00","discovered_at":"2026-05-14T18:04:04.542941+00:00","generated_at":"2026-06-25T20:01:03.981268+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Achieve reports Q1 net loss $7.6M; positive Phase 3 ORCA-2 cytisinicline results","bullets":["Net loss of $7.6M for Q1 2022; cash & equivalents $36.4M as of March 31, 2022.","Phase 3 ORCA-2 cytisinicline met primary endpoints: 12-week abstinence 32.6% vs 7.0% placebo.","Updated SVB debt facility provides remaining $10M available through April 2023.","Appointed Dr. Vaughn Himes (CTO of Seagen) to Board of Directors in March 2022.","Operating expenses $7.2M for Q1; shares outstanding 9,681,855 as of May 12, 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-22-019857","json":"https://secwatch.observer/filing/0001564590-22-019857.json","markdown":"https://secwatch.observer/filing/0001564590-22-019857.md","text":"https://secwatch.observer/filing/0001564590-22-019857.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/949858/000156459022019857/0001564590-22-019857-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/949858/000156459022019857/achv-8k_20220512.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T20:01:03.981268+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}